VRTX

Vertex Pharmaceuticals
D

VRTX

Arincen81/100B

Vertex Pharmaceuticals P/E ratio

Vertex Pharmaceuticals's P/E ratio is 34.93: its share price of 547.03 over its earnings per share of 15.66 over the last twelve months.

Today
34.93
Forward P/E, next 12 months
27.51
PEG ratio
2.03
Average, 5 years
29.22
Low, 5 years
21.62
High, 5 years
35.07

P/E ratio = price ÷ EPS (last 12 months) = 547.03 ÷ 15.66 = 34.93

Each day's closing price over the earnings per share of the last four quarters reported by that day (basic EPS, adjusted for splits). The P/E moves with the price every day and with the earnings at each report.

The forward P/E divides the price by the analysts' average EPS estimate for the next twelve months: the fiscal year in progress for the months left in it, the next one for the rest. For past days it uses each year's latest estimate, as the estimates of the time were not recorded (we keep a daily copy from November 2026), so the past line reads the price against the earnings expected by the time each year was reported.

P/E ratio by year and by quarter

Fiscal yearPeriod endingP/E ratioForward P/EMarket capNet income
FY2027 · Estimate31 Dec 202727.13———
FY2026 · Estimate31 Dec 202630.00———
Today34.9327.51138.65B3.98B
FY202531 Dec 202529.3224.88115.92B3.95B
FY202431 Dec 2024—21.79103.70B-535.60M
FY202331 Dec 202328.9715.04104.86B3.62B
FY202231 Dec 202222.2615.0473.96B3.32B
FY202131 Dec 202124.1615.0456.59B2.34B
FY202031 Dec 202022.6518.2461.41B2.71B
FY201931 Dec 201947.7721.0656.21B1.18B
FY201831 Dec 201820.1939.1242.14B2.09B
FY201731 Dec 2017406.9839.1237.29B91.64M
FY201631 Dec 2016—39.1217.95B-84.03M
FY201531 Dec 2015—156.8830.30B-588.18M
FY201431 Dec 2014—12,615.6327.91B-742.75M
FY201331 Dec 2013—12,615.6316.70B-687.55M
FY201231 Dec 2012—12,615.638.88B-51.14M
FY201131 Dec 2011165.2415.096.80B41.18M
FY201031 Dec 2010——7.02B-754.63M
FY200931 Dec 2009——7.42B-642.18M
FY200831 Dec 2008——4.27B-459.85M
FY200731 Dec 2007——3.00B-391.28M
FY200631 Dec 2006——4.24B-206.89M
FY200531 Dec 2005——2.47B-203.42M
FY200431 Dec 2004——830.50M-166.25M
FY200331 Dec 2003——796.99M-196.77M
FY200231 Dec 2002——1.20B-108.62M
FY200131 Dec 2001——1.83B-66.23M
FY200031 Dec 2000——4.84B-39.66M
FY199931 Dec 1999——893.13M-41.00M
FY199831 Dec 1998——752.65M-33.10M
FY199731 Dec 1997——800.71M-19.80M
FY199631 Dec 1996——752.34M-40.00M
FY199531 Dec 1995——452.18M-21.50M
FY199431 Dec 1994——235.71M-17.60M
FY199331 Dec 1993115.63—231.25M2.00M
FY199231 Dec 1992——118.39M-8.50M
FY199131 Dec 1991——107.79M-5.10M
FY199031 Dec 1990——88.54M-4.30M

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters. A forecast year's P/E is today's price over the analysts' EPS estimate for that year.

See also:Market cap,P/S ratio,ROE (return on equity),Debt to equity,Current ratio,All ratios

Common questions about Vertex Pharmaceuticals's P/E ratio

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.